Global Obsessive Compulsive Disorder Market, By Drug Class (Tricyclic Obsessive compulsive disorder, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, Others), Indication (Major Depressive Disorder, Anxiety Disorders, Attention Deficit Hyperactivity Disorder, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029.
Obsessive Compulsive Disorder Market Analysis and Size
The global obsessive compulsive disorder market is expected to witness significant growth during the forecast period. The pharma and healthcare sector is swiftly developing with innovations in technology, increasing healthcare spending and improving healthcare facilities and systems. Several hospitals, ambulatory surgical care centers and clinics globally are adopting advanced devices and equipment. The ongoing pandemic is rapidly changing the pharma and healthcare sector dynamics. Numerous countries are facing challenges such as shortage of medicines, vaccines, healthcare devices in hospitals. This is anticipated to open huge growth opportunities for market players in the upcoming years.
Data Bridge Market Research analyses a growth rate in the global obsessive compulsive disorder market in the forecast period 2022-2029. The expected CAGR of global obsessive compulsive disorder market is tend to be around 10.2% in the mentioned forecast period. The market was valued at USD 505.1 million in 2021, and it would grow upto USD 1098.58 million by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Obsessive Compulsive Disorder Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Tricyclic Obsessive compulsive disorder, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, Others), Indication (Major Depressive Disorder, Anxiety Disorders, Attention Deficit Hyperactivity Disorder, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Ampio Pharmaceuticals Inc. (U.S.), Lilly (U.S.), Mallinckrodt plc (U.K.), Amneal Pharmaceutical Inc (U.S.), Aurobindo Pharma (India), Par Pharmaceutical (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Obsessive compulsive disorder is a type of mental illness characterized by repeated unreasonable thoughts and uncontrollable fears resulting in repetitive action or activity by a person. The obsessive-compulsive usually induces individual to throws themselves into particular thought or fear. There are common obsessions associated with it such as contamination, sexual, violent, identity, responsibility and many more.
Global Obsessive Compulsive Disorder Market Dynamics
Drivers
- High Prevalence of Infectious Diseases
The countrywide overall incidence of all infectious disease syndromes was 71.8 per 10,000 population between 2009 and 2017. The average number of all infectious diseases was around 14,519 (range 5229 to 55,132) per year. This boosts the market growth.
- Increasing Demand of Antidepressants
There are various drugs associated with the treatment of OCDs. Among them, antidepressants boost the market growth rapidly. In 2021, the antidepressants segment is dominating the global obsessive obsessive-compulsive disorder drug market because of advancements in the anti-anxiety, antipsychotic and antidepressant drugs, and the growing development of newer treatment are projected to dominate the market.
Opportunities
- Increase Prevalence of Mental Illness
The increasing prevalence of anxiety disorder market is surely affecting the growth of the market. As per the reports of WHO in 2017, over 300 million people of all age groups globally are suffering from depression, and in that, around 800,000 people die from suicide, and it was found that anxiety disorders and depression are the major cause. Additionally, as per the Anxiety and Depression Association of America, anxiety disorders are witnessed as the most common mental illness disease in the U.S., affecting around 18% of the population. This boosts the market growth.
- Increasing Demand for Retail Pharmacies
The rise in the number of drugs for OCD being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Emergence of OCD
OCD can lead to varied comorbidities that act as a hindrance to the market. Comorbidities such as Eating disorders, Anxiety disorders, Substance use disorders, Schizophrenia, Schizoaffective disorder, Bipolar disorder, Depressive disorders, Trichotillomania, Body dysmorphic disorder, Excoriation (skin-picking) disorder are commonly witnessed in these patients.
- High Cost
The huge expenditure required for treatment process hamper the market growth. The medications involved in this diseased consition such as tricyclic obsessive compulsive disorder, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors induce a high cost to the treatment.
This global obsessive compulsive disorder market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global obsessive compulsive disorder market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Obsessive Compulsive Disorder Market
The COVID-19 pandemic has prompted global measures to prevent infection. Experts assume that it is particularly affecting people with obsessive-compulsive disorder (OCD), especially those with washing compulsions. COVID-19 compelled people to wash their hands multiple times, clean their houses, and many more. It also indiced in people the feeling of anxietyand depression. Thus, covid-19 significantly impacted the global obsessive compulsive disorder market.
Recent Developments
In June 2021, Teva Pharmaceuticals USA, Inc., declared the U.S. launch of its generic version once-daily SOOLANTRA (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea. With its launch of products, Teva has become a global leader in generic and specialty medicines with a portfolio entailing over 3,500 products in nearly every therapeutic area.
Global Obsessive Compulsive Disorder Market Scope
The global obsessive compulsive disorder market is segmented on the basis of drug class, indication, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Tricyclic Obsessive compulsive disorder
- Selective Serotonin Reuptake Inhibitors
- Serotonin-Norepinephrine Reuptake Inhibitors
- Monoamine Oxidase Inhibitors
- Serotonin Antagonist and Reuptake Inhibitors
- Others
Indication
- Major Depressive Disorder
- Anxiety Disorders
- Attention Deficit Hyperactivity Disorder
- Others
Route of Administration
- Oral
- Injectable
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Obsessive Compulsive Disorder Market Regional Analysis/Insights
The global obsessive compulsive disorder market is analysed and market size insights and trends are provided by drug class, indication, route of administration, end-user and distribution channel as referenced above.
The major countries covered in the global obsessive compulsive disorder market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the high prevalence of obsessive-compulsive disorder, presence of refined healthcare expenditure and increased patient awareness level
Asia-Pacific is expected to account for the largest market share due to the presence of global marketed players in this region and growing cases of mental illness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Obsessive Compulsive Disorder Market Share Analysis
The global obsessive compulsive disorder market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global obsessive compulsive disorder market
Key players operating in the global obsessive compulsive disorder market include:
- Pfizer Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Novartis AG (Switzerland)
- Amgen Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Merck & Co Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- AstraZeneca (U.K.)
- Ampio Pharmaceuticals Inc. (U.S.)
- Lilly (U.S)
- Mallinckrodt plc (U.K.)
- Amneal Pharmaceutical Inc (U.S.)
- Aurobindo Pharma (India)
- Par Pharmaceutical (U.S.)
SKU-